Cardiovascular outcomes trials for non-cardiac drugs should be “mechanistically sensitive” to the potential safety concerns posed by a particular product and not automatically focused on the traditional endpoint of major ischemic events, cardiology experts on FDA’s Endocrinologic and Metabolic Drugs Advisory Committee agreed.
During the Sept